ResultsIQ

ResultsIQ › Latest results › GPT Healthcare Limited

GPT Healthcare Limited Q3 FY26 earnings call summary

NSE: GPTHEALTH · BSE: 544131

Earnings call of 3 Feb 2026, summarised by AI from the filing.

GPT Healthcare 9M FY26 revenue ₹350.5 cr, up 12.12%; Raipur EBITDA breakeven expected in 6-8 months.

Key takeaways

  1. Dum Dum restructuring Dum Dum occupancy declined due to reduced length of stay and department restructuring; double-digit growth expected next year.
  2. Occupancy driver Occupancy improvement driven by new departments like oncology in Agartala and cardiac surgeries in Dum Dum.
  3. Bangladesh risk Bangladesh patient volumes at Agartala still not back to previous levels, impacting demand.

Original filing on BSE

GPT Healthcare Limited Q1 FY27 results

As filed: Revenue ₹126 cr (+18% year on year), EBITDA ₹24.2 cr (+42% year on year), PAT ₹12.7 cr (+59% year on year), EBITDA margin 19.2% (+326 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹126 cr (+25% year on year), EBITDA ₹23.4 cr (+17% year on year), PAT ₹14.6 cr (+12% year on year), EBITDA margin 18.5% (−132 bps). Score 82 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin fell 132 bps year on year. Tax rate 8%. Share price after the results: +4.4% in 30 days (Nifty 500: +2.9%).
  • Q3 FY26: Revenue ₹120 cr (+18% year on year), EBITDA ₹20.7 cr (−6% year on year), PAT ₹9.4 cr (−22% year on year), EBITDA margin 17.2% (−433 bps). Score 47 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 433 bps year on year. Profit fell 15% from last quarter. Share price after the results: −5.7% in 30 days (Nifty 500: −1.9%).
  • Q2 FY26: Revenue ₹119 cr (+12% year on year), EBITDA ₹23.0 cr (−4% year on year), PAT ₹11.0 cr (−27% year on year), EBITDA margin 19.3% (−331 bps). Score 30 of 100, Below trend. EBITDA margin fell 331 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.4% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹107 cr (+9% year on year), EBITDA ₹17.0 cr (−11% year on year), PAT ₹8.0 cr (−20% year on year), EBITDA margin 15.9% (−350 bps). Score 27 of 100, Below trend. EBITDA margin fell 350 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 38% from last quarter. Share price after the results: −13.8% in 30 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹101 cr (+2% year on year), EBITDA ₹20.0 cr (−13% year on year), PAT ₹13.0 cr (0% year on year), EBITDA margin 19.8% (−343 bps). Score 24 of 100, Below trend. EBITDA margin fell 343 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.6% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹102 cr (+5% year on year), EBITDA ₹22.0 cr (0% year on year), PAT ₹12.0 cr (+9% year on year), EBITDA margin 21.6% (−111 bps). Score 36 of 100, Below trend. EBITDA margin fell 111 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 4% from last quarter.
  • Q2 FY25: Revenue ₹106 cr, EBITDA ₹24.0 cr, PAT ₹15.0 cr, EBITDA margin 22.6%. Not scored. No result for the same quarter last year.

Past price moves after results do not indicate future moves. Not a recommendation.

GPT Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.